The IAAM LTBP4 Haplotype is Protective Against Dystrophin-Deficient Cardiomyopathy

Abstract

Background: Dilated cardiomyopathy (DCM) is a major complication of, and leading cause of mortality in Duchenne muscular dystrophy (DMD). Its severity, age at onset, and rate of progression display wide variability, whose molecular bases have been scarcely elucidated. Potential DCM-modifying factors include glucocorticoid (GC) and cardiological treatments, DMD mutation type and location, and variants in other genes.

Methods and results: We retrospectively collected 3138 echocardiographic measurements of left ventricular ejection fraction (EF), shortening fraction (SF), and end-diastolic volume (EDV) from 819 DMD participants, 541 from an Italian multicentric cohort and 278 from the Cooperative International Neuromuscular Group Duchenne Natural History Study (CINRG-DNHS). Using generalized estimating equation (GEE) models, we estimated the yearly rate of decrease of EF (-0.80%) and SF (-0.41%), while EDV increase was not significantly associated with age. Utilizing a multivariate generalized estimating equation (GEE) model we observed that mutations preserving the expression of the C-terminal Dp71 isoform of dystrophin were correlated with decreased EDV (-11.01 mL/m2, p = 0.03) while for dp116 were correlated with decreased EF (-4.14%, p = <0.001). The rs10880 genotype in the LTBP4 gene, previously shown to prolong ambulation, was also associated with increased EF and decreased EDV (+3.29%, p = 0.002, and -10.62 mL/m2, p = 0.008) with a recessive model.

Conclusions: We quantitatively describe the progression of systolic dysfunction progression in DMD, confirm the effect of distal dystrophin isoform expression on the dystrophin-deficient heart, and identify a strong effect of LTBP4 genotype of DCM in DMD.

Keywords: Duchenne muscular dystrophy; LTBP4; dilated cardiomyopathy; genetic modifiers; glucocorticoid treatment.

Fig. 1

Scatter plots of ejection fraction (%) (A), shortening fraction (%) (B) and end-diastolic volume (mL/m²) (C) by age, grouped by GC treatment at evaluation time. Pathological thresholds are marked by dashed lines.

Fig. 2

Scatter plots of ejection fraction (%) (A), end diastolic volume (mL/m²) (B) by age, grouped by LTBP4 genotype. Pathological thresholds are marked by the dashed lines.

Fig. 3

Scatter plots of ejection fraction (%) (A), end diastolic volume (mL/m²) (B) by age, grouped by relevant DMD mutation type. Pathological thresholds are marked by the dashed lines.